| ALLR |
Allarity Therapeutics, Inc. |
62%
|
Reciprocal relationship from ALLR graph: Reciprocal relationship from ALUR graph: part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization A… |
| ALLURION-AUSTRALIA-PTY-LTD |
ALLURION-AUSTRALIA-PTY-LTD |
62%
|
her Countries 1,712 3,451 Total Revenues $ 2,947 $ 5,580 9 There was no revenue generated in the United States from sales of the Allurion Balloon during each of the three months ended March 31, 2026 … |
| ALLURION-TECHNOLOGIES-HOLDINGS-INC |
ALLURION-TECHNOLOGIES-HOLDINGS-INC |
62%
|
part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization Allurion Technologies, Inc. (“Allurion” or the “Company”) is a vertically integrate… |
| ALLURION-TECHNOLOGIES-INC |
ALLURION-TECHNOLOGIES-INC |
62%
|
nical Trial Agreement, dated June 30, 2022, by and between the Company and Vanderbilt (the "Clinical Trial Agreement"), related to the clinical trial for the Smart Capsule by failing to reimburse med… |
| ALLURION-TECHNOLOGIES-LLC |
ALLURION-TECHNOLOGIES-LLC |
62%
|
nical Trial Agreement, dated June 30, 2022, by and between the Company and Vanderbilt (the "Clinical Trial Agreement"), related to the clinical trial for the Smart Capsule by failing to reimburse med… |
| ALLURION-TECHNOLOGIES-OPCO-INC |
ALLURION-TECHNOLOGIES-OPCO-INC |
62%
|
nical Trial Agreement, dated June 30, 2022, by and between the Company and Vanderbilt (the "Clinical Trial Agreement"), related to the clinical trial for the Smart Capsule by failing to reimburse med… |
| COMPANY-ALLURION-OPCO-ALLURION-AUSTRALIA-PTY-LTD |
COMPANY-ALLURION-OPCO-ALLURION-AUSTRALIA-PTY-LTD |
62%
|
Omnibus Amendment (the "RIFA Amendment") by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly-owned su… |
| COMPUTE-HEALTH-ACQUISITION-CORP |
COMPUTE-HEALTH-ACQUISITION-CORP |
62%
|
part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization Allurion Technologies, Inc. (“Allurion” or the “Company”) is a vertically integrate… |
| COMPUTE-HEALTH-CORP |
COMPUTE-HEALTH-CORP |
62%
|
part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization Allurion Technologies, Inc. (“Allurion” or the “Company”) is a vertically integrate… |
| COMPUTE-HEALTH-LLC |
COMPUTE-HEALTH-LLC |
62%
|
part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization Allurion Technologies, Inc. (“Allurion” or the “Company”) is a vertically integrate… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
her Countries 1,712 3,451 Total Revenues $ 2,947 $ 5,580 9 There was no revenue generated in the United States from sales of the Allurion Balloon during each of the three months ended March 31, 2026 … |
| FUNDAMENTAL-CHANGE-COMPANY |
FUNDAMENTAL-CHANGE-COMPANY |
62%
|
FVO election of ASC 825 as the notes contain embedded derivatives, including the conversion upon Stockholder Approval, the conversion upon a Fundamental Change Company Notice, the conversion upon a M… |
| LEAVITT-EQUITY-PARTNERS-LLC |
LEAVITT-EQUITY-PARTNERS-LLC |
62%
|
$ 1.23 Risk-free interest rate 3.5 % 3.5 % Expected term (in years) 2.3 2.6 Expected volatility 145.0 % 145.0 % RTW Convertible Notes The RTW Convertible Notes are accounted for using the FVO electio… |
| NYSE-LISTED-COMPANY |
NYSE-LISTED-COMPANY |
62%
|
nical Trial Agreement, dated June 30, 2022, by and between the Company and Vanderbilt (the "Clinical Trial Agreement"), related to the clinical trial for the Smart Capsule by failing to reimburse med… |
| OTC-MARKET-GROUP-INC |
OTC-MARKET-GROUP-INC |
62%
|
5 with the SEC, which would result in the delisting of the Company’s Common Stock and Warrants from the NYSE on the tenth day after the Form 25 is filed. As a result of the suspension in trading and … |
| PRESENTATION-ORGANIZATION-ALLURION-TECHNOLOGIES- |
PRESENTATION-ORGANIZATION-ALLURION-TECHNOLOGIES- |
62%
|
part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization Allurion Technologies, Inc. (“Allurion” or the “Company”) is a vertically integrate… |
| USA-LLC |
USA-LLC |
62%
|
$ 1.23 Risk-free interest rate 3.5 % 3.5 % Expected term (in years) 2.3 2.6 Expected volatility 145.0 % 145.0 % RTW Convertible Notes The RTW Convertible Notes are accounted for using the FVO electio… |
